Business Context and Reporting Period
Company: ICU Medical, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2002
Industry: Medical Devices (Disposable I.V. connection systems and blood collection needles)
ICU Medical is a leader in developing proprietary, disposable medical connection systems designed to prevent needlestick injuries and exposure to infectious diseases (Hepatitis B/C, HIV). The company's primary product is the CLAVE(R) needleless connector, which accounted for 67% of revenue in 2002. In October 2002, the company acquired Bio-Plexus, Inc., adding the Punctur-Guard(R) line of blood collection needles to its portfolio. The company is strategically transitioning from a component manufacturer to a producer of complete custom and generic I.V. systems.
Key Financial Metrics
| Metric (in thousands) | 2002 | 2001 | 2000 |
|---|---|---|---|
| Total Revenue | $87,807 | $69,055 | $56,191 |
| Net Sales | $84,218 | $69,055 | $56,191 |
| Gross Profit | $51,343 | $40,123 | $32,404 |
| Gross Margin | 57% | 58% | 58% |
| Operating Income | $30,000 | $22,119 | $16,622 |
| Operating Margin | 34% | 32% | 30% |
| Net Income | $19,682 | $15,387 | $11,788 |
| Diluted EPS | $1.28 | $1.06 | $0.87 |
| Cash Flow from Operations | $28,097 | $24,329 | $13,462 |
| Cash & Liquid Investments | $88,465 | $73,027 | $50,786 |
| Working Capital | $102,564 | $79,736 | $57,718 |
| Long-term Debt | $0 | $0 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 27% to $87.8 million, driven by a 14% increase in CLAVE product sales and a 64% surge in custom I.V. system sales.
- Customer Concentration: Abbott Laboratories remained the largest customer, accounting for 57% of 2002 revenue (up from 53% in 2001). Sales to Abbott grew to $50.0 million.
- Acquisition Impact: The acquisition of Bio-Plexus in October 2002 added the Punctur-Guard product line, contributing $1.2 million in sales for the two-month period it was owned.
- Contract Termination: The supply agreement with B.Braun Medical, Inc. terminated on December 31, 2002. Revenue from B.Braun declined to $9.9 million (from $12.9 million in 2001) as the company ceased selling CLAVE products to them.
- Margin Pressure: Gross margin declined slightly to 57% from 58% due to unabsorbed overhead in Q4 2002 caused by production disruptions during enterprise software implementation and planned facility maintenance.
- Inventory Build-up: Inventories increased significantly by 261% (from $1.6 million to $5.7 million), largely due to deferred shipments to Abbott and increased raw material stocking to mitigate supply chain risks.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Strategic Shift: Management is actively reducing dependence on the CLAVE product by expanding custom I.V. systems and blood collection devices. The "SetSource" program with Abbott is expected to drive significant growth in custom systems.
- Capital Expenditures: Estimated capital expenditures for 2003 are approximately $12 million, focused on completing a $7.2 million expansion in Mexico (including a sterilization facility) and purchasing new molding and assembly equipment.
- Product Pipeline: The company plans to launch an infusion device using Punctur-Guard technology in Q2 2003 and expects to apply for FDA clearance for a new I.V. connector in the second half of 2003.
- Stock Repurchases: The company repurchased 318,300 shares of common stock for $8.6 million in early 2003.
Risks and Contingencies
- Customer Concentration: Heavy reliance on Abbott (57% of revenue) poses a significant risk; loss of this customer would materially adversely affect operations.
- Legal Proceedings: The company is pursuing patent infringement litigation against B.Braun regarding the UltraSite product and Medtronic Minimed. Outcomes are uncertain.
- Regulatory Approval: Future growth depends on FDA clearance for new products, which is not guaranteed.
- Competition: The market is intensely competitive with large players (Baxter, BD, B.Braun) and downward pressure on selling prices.
Investor Verification Checklist
- Abbott Dependency: Verify the stability of the Abbott contract and the potential impact of any future contract renegotiations or terminations.
- Inventory Levels: Assess the justification for the 261% increase in inventory and the risk of obsolescence or write-downs.
- B.Braun Litigation: Monitor the status of the patent infringement suit against B.Braun and the potential for damages or injunctions.
- Margin Sustainability: Evaluate whether the 57% gross margin is sustainable given the integration of the lower-margin Punctur-Guard line and planned facility expansions.
- Capital Allocation: Review the execution of the $12 million 2003 capital expenditure plan, particularly the Mexico facility expansion.